Malaria research: Host-parasite interactions and new developments in chemotherapy, immunology and vaccinology

Current Opinion in Infectious Diseases

Volumn 13, Issue 5, 2000, Pages 431-443

  Perlmann, Peter ^a   Björkman, Anders ^b  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; IMMUNOLOGICAL ADJUVANT; SYNTHETIC PEPTIDE; VIRUS VECTOR;

CELLULAR IMMUNITY; CHEMOTHERAPY; HOST PARASITE INTERACTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION CONTROL; MALARIA; PARASITE VIRULENCE; PLASMODIUM FALCIPARUM; PREVALENCE; REVIEW; VACCINATION;

EID: 0033760672     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200010000-00002     Document Type: Review

References (123)

1. The cytotoxic T-lymphocyte epitope of the Plasmodium falciparum circumsporozoite protein also modulates the efficiency of receptor-ligand interaction with hepatocytes
2. The A-domain and the thrombospondin-related motif of Plasmodium falciparum TRAP are implicated in the invasion process of mosquito salivary glands
3. Conservation of a gliding motility and cell invasion machinery in apicomplexan parasites
4. Broadly distributed T cell reactivity, with no immunodominant loci, to the pre-erythrocytic antigen thrombospondin-related adhesive protein of Plasmodium falciparum in West Africans
5. CTRP is essential for mosquito infection by malaria ookinetes
6. The genome of the malaria parasite
7. Genome projects, genetic analysis, and the changing landscape of malaria research
8. A genetic map and recombination parameters of the human malaria parasite Plasmodium falciparum
9. A shotgun optical map of the entire Plasmodium falciparum genome
10. Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum
11. The complete nucleotide sequence of chromosome 3 of Plasmodium falciparum
12. Shotgun DNA microarrays and stage-specific gene expression in Plasmodium falciparum malaria
13. Karyotype and synteny among the chromosomes of all four species of human malaria parasite
14. Origin, targeting, and function of the apicomplexan plastid
15. Antigenic variation in Plasmodium falciparum: Mechanisms and consequences
16. The role of variant surface antigens on malaria-infected red blood cells
17. Analysis of Plasmodium falciparum PfEMP-1/var genes suggests that recombination rearranges constrained sequences
18. Virulence and transmission success of the malarial parasite Plasmodium falciparum
19. Malaria transmission and naturally acquired immunity to PfEMP-1
20. Antibody recognition of Plasmodium falciparum erythrocyte surface antigens in Kenya: Evidence for rare and prevalent variants
21. Antibodies to variable Plasmodium falciparum-infected erythrocyte surface antigens are associated with protection from novel malaria infections
22. Stevor and rif are Plasmodium falciparum multicopy gene families which potentially encode variant antigens
23. Rifins: A second family of clonally variant proteins expressed on the surface of red cells infected with Plasmodium falciparum
24. Small, clonally variant antigens expressed on the surface of the Plasmodium falciparum-infected erythrocyte are encoded by the rif gene family and are the target of human immune responses
25. EBL-1, a putative erythrocyte binding protein of Plasmodium falciparum, maps within a favored linkage group in two genetic crosses
26. Interleukin 10-mediated immunosuppression by a variant CD4 T cell epitope of Plasmodium falciparum
27. A preliminary continental risk map for malaria mortality among African children
28. An evaluation of poor pregnancy outcomes among Burundian refugees in Tanzania
29. Immunity to non-cerebral severe malaria is acquired after one or two infections
30. Cognitive sequelae of severe malaria with impaired consciousness
31. Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: A randomised, controlled intervention study
32. Effect of vitamin A supplementation on morbidity due to Plasmodium falciparum in young children in Papua New Guinea: A randomised trial
33. Wide-scale installation of insecticide-treated curtains confers high levels of protection against malaria transmission in a hyperendemic area of Burkina Faso
34. Permethrin-treated chaddars and top-sheets: Appropriate technology for protection against malaria in Afghanistan and other complex emergencies
35. Cost-effectiveness of malaria control in sub-Saharan Africa
36. A cohort study of Plasmodium falciparum diversity during the dry season in Ndiop, a Senegalese village with seasonal, mesoendemic malaria
37. Genetic analysis of Plasmodium falciparum infections on the north-western border of Thailand
38. Genetic characterization of an epidemic of Plasmodium falciparum malaria among Yomomani Amerindians
39. Cross-species interactions between malaria parasites in humans
40. Complexity of Plasmodium falciparum infections is consistent over time and protects against clinical disease in Tanzanian children
41. Transmission control and drug resistance in malaria: A crucial interaction
42. Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: A double-blind, randomised, controlled trial
43. Analysis of mefloquine resistance and amplification of pfmdr1 in multidrug-resistant Plasmodium falciparum isolates from Thailand
44. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum
45. Association of cg2 and pfmdr1 genotype with chloroquine resistance in field samples of Plasmodium falciparum from Nigeria
46. Averting a malaria disaster
47. The effect of artesunate combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro
48. Synergism of benflumetol and artemether in Plasmodium falciparum
49. Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in Uganda: Correlation with polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes
50. Plasmodium falciparum: Selection of serine 108 of dihydrofolate reductase during treatment of uncomplicated malaria with co-trimoxazole in Ugandan children
51. Molecular epidemiology of malaria in Yaounde, Cameroon IV. Evolution of pyrimethamine resistance between 1994 and 1998
52. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia
53. Pharmacokinetics of benflumetol given as a fixed combination artemether-benflumetol (CGP 56697) in Thai patients with uncomplicated falciparum malaria
54. High and variable frequencies of CYP2C19 mutations: Medical consequences of poor drug metabolism in Vanuatu and other Pacific islands
55. The antimalarial triazine WR99210 and the prodrug PS-15: Folate reversal of in vitro activity against Plasmodium falciparum and a non-antifolate mode of action of the prodrug
56. Potent antimalarial activity of clotrimazole in in vitro cultures of Plasmodium falciparum
57. Antisense oligonucleotides targeting malarial aldolase inhibit the asexual erythrocytic stages of Plasmodium falciparum
58. An overview of Plasmodium protein kinases
59. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drug
60. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells
61. Mapping the binding domains involved in the interaction between the Plasmodium falciparum knob-associated histidine-rich protein (KAHRP) and the cytoadherence ligand P. falciparum erythrocyte membrane protein 1 (PfEMP1)
62. The cytoadherence linked asexual gene family of Plasmodium falciparum: Are there roles other than cytoadherence?
63. Rouleaux-forming serum proteins are involved in the rosetting of Plasmodium falciparum-infected erythrocytes
64. Multiple human serum components act as bridging molecules in rosette formation by Plasmodium falciparum-infected erythrocytes
65. Cytoadherence characteristics of Plasmodium falciparum-infected erythrocytes from Malawian children with severe and uncomplicated malaria
66. CD36 peptides that block cytoadherence define the CD36 binding region for Plasmodium falciparum-infected erythrocytes
67. Identification of a Plasmodium falciparum intercellular adhesion molecule-1 binding domain: A parasite adhesion trait implicated in cerebral malaria
68. Blood group A antigen is a coreceptor in Plasmodium falciparum rosetting
69. Cytoadherence, pathogenesis and the infected red cell surface in Plasmodium falciparum
70. Molecular mechanisms of cytoadherence in malaria
71. Differential effect and interaction of monocytes, hyperimmune sera and immunoglobulin G on the growth of asexual stage Plasmodium falciparum parasites
72. High immunoglobulin G2 (IgG2) and low IgG4 levels are associated with human resistance to Plasmodium falciparum malaria
73. IgE and tumor necrosis factor in malaria infection
74. Interethnic differences in the humoral response to non-repetitive regions of the Plasmodium falciparum circumsperozoite protein
75. Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3
76. Malaria parasite-specific Th1-like T cells simultaneously reduce parasitemia and promote disease
77. Human γδT cells that inhibit the in vitro growth of the asexual blood stages of the Plasmodium falciparum parasite express cytolytic and proinflammatory molecules
78. + TCRαβ intermediate cells increase during experimental malaria infection and are able to exhibit inhibitory activity against the parasite liver stage in vitro
79. CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells
80. Immune effector mechanisms in malaria
81. A role for cytokines in potentiation of malaria vaccines through immunological modulation of blood stage infection
82. The prognostic and pathophysiologic role of pro- and antiinflammatory cytokines in severe malaria
83. A low interleukin-10 tumor necrosis factor-α ratio is associated with malaria anemia in children residing in a holoendemic malaria region in western Kenya
84. Interleukin-10 responses to liverstage antigen 1 predict human resistance to Plasmodium faliparum
85. Plasma levels of the interleukin-6 cytokine family in persons with severe Plasmodium falciparum malaria
86. Maintaining the immunological balance in parasitic infections: A role for TGF-β?
87. Cytokine expression in the brain in human cerebral malaria
88. Early cytokine induction by Plasmodium falciparum is not a classical endotoxin-like process
89. A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria
90. TNFα*2 marks high risk of severe disease during Plasmodium falciparum malaria and other infections in Sri Lankans
91. Severe malarial anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles
92. A dichotomous role for nitric oxide in protection against blood stage malaria infection
93. Nitric oxide and infectious diseases
94. Nitric oxide, malaria, and anemia: Inverse relationship between nitric oxide production and hemoglobin concentration in asymptomatic, malaria-exposed children
95. Blood mononuclear cell nitric oxide production and plasma cytokine levels in healthy Gabonese children with prior mild or severe malaria
96. High levels of inducible nitric oxide synthase mRNA are associated with increased monocyte counts in blood and have a beneficial role in Plasmodium falciparum malaria
97. Placental pathology in malaria, a histological, immunohistochemical and quantitative study
98. Hyperexpression of ICAM-1 and CD36 in placentas infected with Plasmodium falciparum: A possible role of these molecules in sequestration of infected red blood cells in placentas
99. Cytoadherence of Plasmodium falciparum-infected erythrocytes in the human placenta
100. Ex vivo desequestration of Plasmodium falciparum-infected erythrocytes from human placenta by chondroitin sulfate A
101. The adhesion of Plasmodium falciparum-infected erythrocytes to chondroitin sulfate A is mediated by P. falciparum erythrocyte membrane protein 1
102. Plasmodium falciparum domain mediating adhesion to chondroitin sulfate A: A receptor for human placental infection
103. Plasmodium falciparum isolates from infected pregnant women and children are associated with distinct adhesive and antigenic properties
104. Development of antibodies against chondroitin sulfate A-adherent Plasmodium falciparum in pregnant women
105. Immunity to placental malaria. I. Elevated production of interferon-γ by placental blood mononuclear cells is associated with protection in an area with high transmission of malaria
106. Malaria during pregnancy: Parasites, antibodies and chondroitin sulphate A
107. A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in the Gambia
108. Serological responses of Gambian children to immunization with the malaria vaccine SPf66
109. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant
110. Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine
111. Expression and immunogenicity of a liver stage malaria epitope presented as a foreign peptide on the surface of RNA-free MS2 bacteriophage capsids
112. Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice
113. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys
114. Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys
115. Potentiation of immune response against the RESA peptides of Plasmodium falciparum by incorporating a universal T-cell epitope (CS-T3) and an immunomodulator (Polytuftsin), and delivery through liposomes
116. Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies
117. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
118. + T cell immunogenicity and protective efficacy in the influenza and malaria models
119. + T cells in the Plasmodium yoelii model
120. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers
121. Construction and immunogenicity of DNA vaccine plasmids encoding four Plasmodium vivax candidate vaccine antigens
122. Plasmid DNA malaria vaccine: Tissue distribution and safety studies in mice and rabbits
123. Plasmid DNA malaria vaccine: The potential for genomic integration after intramuscular injection